💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Didanosine

CHEMBL1460 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
236.2 g/mol
LogP
-1.2
Phase
4

A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.

分子量

236.2300 g/mol

LogP

-1.20

TPSA

88.70 Ų

リピンスキーの五則

適合

治療領域

Cardiovascular Disease Lymphoma HIV/AIDS Hepatitis C Tuberculosis

作用機序

Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1

                

                

                
                

                    
InChI

                    
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C10H12N4O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
回転可能結合数

                        
2

                    

                    
                    
                    

                        
重原子数

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Didanosine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1460.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135398739.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.